Interferon alpha2 recombinant and epidermal growth factor modulate proliferation and hypusine synthesis in human epidermoid cancer KB cells.
We previously found that interferon alpha2 recombinant (IFNalpha) increases the expression of epidermal growth factor receptor (EGF-R) in the human epidermoid cancer KB cell line. Here we report the effects of IFNalpha and epidermal growth factor (EGF) on KB cell cycle kinetics. IFNalpha (1000 i.u./ml) for 48 h decreased the S-phase fraction and diminished the expression of Ki67 and proliferating cell nuclear antigen on KB cells. Incubation of IFNalpha-treated KB cells with 10 nM EGF for 12 h reversed these effects. We then studied several biochemical markers of cell proliferation. Ornithine decarboxylase activity was decreased to about one-tenth by IFNalpha and partly restored by EGF. Hypusine is contained only in eukaryotic initiation factor 5A and its levels are correlated with cell proliferation. IFNalpha decreased hypusine synthesis by 75%; exposure of cells to EGF for 12 h restored hypusine synthesis almost completely. We also studied the effects of IFNalpha on the cytotoxicity of the recombinant toxin TP40, which inhibits elongation factor 2 through EGF-R binding and internalization. IFNalpha greatly enhanced the TP40-induced inhibition of protein synthesis in KB cells. In conclusion, IFNalpha, which affects protein synthesis machinery and increases EGF-R expression, enhances the tumoricidal activity of TP40 and hence could be useful in the setting of anti-cancer therapy.
Caraglia
M
M
Cattedra di Oncologia Medica, Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica, Università 'Federico II' di Napoli, Via S. Pansini 5, 80131 Napoli, Italy.
Passeggio
A
A
Beninati
S
S
Leardi
A
A
Nicolini
L
L
Improta
S
S
Pinto
A
A
Bianco
A R
AR
Tagliaferri
P
P
Abbruzzese
A
A
D000970:Antineoplastic Agents / Q000494:pharmacology; D002294:Carcinoma, Squamous Cell / Q000201:enzymology / Q000378:metabolism / Q000473:pathology*; D002453:Cell Cycle / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects*; D004815:Epidermal Growth Factor / Q000494:pharmacology*; D005098:Exotoxins / Q000494:pharmacology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000494:pharmacology*; D008239:Lysine / Q000031:analogs & derivatives* / Q000096:biosynthesis; D009955:Ornithine Decarboxylase / Q000378:metabolism; D009959:Oropharyngeal Neoplasms / Q000201:enzymology / Q000378:metabolism / Q000473:pathology*; D011994:Recombinant Proteins; D016211:Transforming Growth Factor alpha / Q000494:pharmacology; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D005098:Exotoxins; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D016211:Transforming Growth Factor alpha; C083452:transforming growth factor alpha-Pseudomonas exotoxin A (40); C100028:hypusine; D004815:Epidermal Growth Factor; D009955:Ornithine Decarboxylase; D008239:Lysine